The sale is small relative to market cap and by a non-executive director, so it carries limited signal. Monitor for any additional Form 144 filings from executives or larger holders that could indicate a broader insider sentiment shift.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $973.36entry
- T+1 · 13d ago −4.39%α −6.04% · $930.67
- T+5 · 7d ago −5.89%α −5.30% · $916.06
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Christine Poon, a director of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 7,830 shares of common stock with an approximate market value of $7.53 million, to be executed through Goldman Sachs. The shares were acquired through stock option exercises in 2018, 2019, and 2020. This is a routine insider sale by a non-executive director and represents a small fraction of the company's $84.3 billion market cap.
Key Facts
- Christine Poon, a director, filed Form 144 to sell 7,830 shares of Regeneron common stock.
- Estimated sale value is approximately $7.53 million based on the filing.
- Shares were acquired via stock option exercises on January 3, 2018, 2019, and 2020 (2,610 shares each).
- The sale is planned for execution on or after November 2, 2026 through Goldman Sachs & Co. LLC.
- The proposed sale represents about 0.009% of Regeneron's $84.3 billion market cap.
- Recent insider activity over the prior 30 days includes 10 sells totaling $774K, making this filing a larger single insider sale.
Financial Impact
Proposed sale of 7,830 shares valued at approximately $7.53 million, representing about 0.009% of market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur or may be at different terms.
- Director-level sales are generally less informative than C-suite insider sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001958244-26-000681 |
| Document: 0001958244-26-000681-index.html | 0001958244-26-000681 |
| Document: 0001958244-26-000681.txt | 0001958244-26-000681 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers